Dwayne Labatut
Family · Gonzales, LANPI 1760462782
Payments from drug & device makers
Across 274 payments — averaging $14.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AbbVie$1K
- Astellas Pharma US Inc$362
- Abbott$185
- Pfizer$126
- Johnson & Johnson$118
- plus $1K from 27 others
What the payments were for
- Food & beverage$4,052100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 69 | $1,132 |
| AbbVie | 102 | $1,103 |
| Astellas Pharma US Inc | 19 | $362 |
| Abbott | 10 | $185 |
| Pfizer | 7 | $126 |
| Johnson & Johnson | 8 | $118 |
| Novo Nordisk | 8 | $114 |
| Jazz Pharmaceuticals Inc. | 4 | $106 |
| Lilly USA, LLC | 4 | $66 |
| Amgen | 4 | $64 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| Exact Sciences | 3 | $48 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $45 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Antares Pharma, Inc. | 2 | $40 |
| Bayer | 2 | $36 |
| Lundbeck LLC | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Novartis | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Vertex | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
| AstraZeneca | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Abiomed | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$4,052 in reported general payments places this provider in the 85th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 205 | $187,977 |
| MounjaroTirzepatide | 87 | $123,785 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $47,623 |
| EliquisApixaban | 40 | $46,112 |
| TrulicityDulaglutide | 32 | $34,152 |
| XareltoRivaroxaban | 31 | $29,832 |
| OzempicSemaglutide | 12 | $27,984 |
| EntrestoSacubitril/Valsartan | 23 | $21,182 |
| VraylarCariprazine Hcl | 12 | $16,679 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $16,117 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $15,475 |
| MyrbetriqMirabegron | 23 | $14,617 |
| LinzessLinaclotide | 18 | $12,673 |
| NamzaricMemantine Hcl/Donepezil Hcl | 11 | $7,255 |
| VascepaIcosapent Ethyl | 13 | $4,975 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $66 | $157,937119 claims |
| GSKTrelegy Ellipta | $1,132 | $47,62365 claims |
| PfizerEliquis | $126 | $46,11240 claims |
| AbbVieVraylar, Linzess, Namzaric, Synthroid | $1,103 | $37,84054 claims |
| Johnson & JohnsonXarelto | $118 | $29,83231 claims |
| Novo NordiskOzempic | $114 | $27,98412 claims |
| NovartisEntresto | $31 | $21,18223 claims |
| Astellas Pharma US IncMyrbetriq | $362 | $14,61723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,610 family providers in Louisiana.
Other family in Gonzales
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.